Piper Jaffray provided color on Edwards Lifesciences EW. In a research report published today, the rating agency commented on FDA's favorable response to the company's new product.
In the report, Piper Jaffray states, “The FDA held an advisory panel meeting for EW's Sapien® valve on Wednesday.
As expected, the overall view from FDA and a majority of the panelists was
favorable, despite considerable discussion on the higher stroke rates experienced
with the device. We continue to believe Sapien® will be approved on time or early
in the US, and that the Company's goal of $25M in US sales by year end will be
met or exceeded.”
At the moment, Piper Jaffray has an Overweight rating and a price target of $94 placed on the company's stock. On Wednesday, EW lost 2.36% of its value to end the day at $87.53.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in